Actavis PLC (ACT)

ACT on New York Consolidated

305.67USD
3 Jun 2015
Change (% chg)

$-0.04 (-0.01%)
Prev Close
$305.71
Open
$306.92
Day's High
$307.17
Day's Low
$303.78
Volume
1,384,046
Avg. Vol
2,942,435
52-wk High
$317.72
52-wk Low
$201.91

ACT

Chart for ACT

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $120,073.50
Shares Outstanding(Mil.): 392.77
Dividend: --
Yield (%): --

Financials

  ACT Industry Sector
P/E (TTM): -- 36.69 38.84
EPS (TTM): -8.49 -- --
ROI: -2.96 17.28 16.53
ROE: -5.95 18.14 17.62
Search Stocks

Actavis, generic drugmakers hit with class action over Namenda

- Actavis PLC and six generic drugmakers have been hit with a class action accusing them of conspiring to delay the launch of generic versions of Actavis' Alzheimer's drug Namenda.

01 Jun 2015

FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

UPDATE 1-FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON, May 27 - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON, May 27 - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

Actavis cannot drop old version of Alzheimer's drug -appeals court

NEW YORK - Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday.

22 May 2015

UPDATE 2-Actavis cannot drop old version of Alzheimer's drug -appeals court

NEW YORK, May 22 - Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday.

22 May 2015

Actavis cannot drop old version of Alzheimer's drug - appeals court

NEW YORK, May 22 - Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday.

22 May 2015

Actavis says Warner Chilcott unit held talks to settle U.S. probe

- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing.

14 May 2015

Actavis says Warner Chilcott unit held talks to settle U.S. probe

May 14 - Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing.

14 May 2015

Actavis expects Allergan business to drive 2015 growth

- Drugmaker Actavis Plc expects its full-year revenue to rise at least 57 percent, helped by double-digit growth from the Allergan business it bought in March.

11 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks